Eledon Pharmaceuticals, Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing; the provided text does not give a separate Q4-only results breakdown.
Business context
Eledon is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its lead candidate, AT-1501 (renamed tegoprubart in January 2022), is an anti-CD40L antibody being developed for ALS, kidney and islet-cell transplant rejection, and IgA nephropathy (IgAN). The company acquired Anelixis in September 2020 and returned rights to its legacy ENT assets in July 2021, with no reported financial impact from the return.
Financial performance and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $23.7 million | $6.1 million |
| General and administrative expense | $13.1 million | $10.1 million |
| Total operating expenses | $36.9 million | $18.5 million |
| Net loss | $34.5 million | $22.8 million |
| Net cash used in operating activities | $28.9 million | $15.2 million |
| Cash and cash equivalents, year-end | $84.8 million | $114.2 million |
- Working capital was $83.9 million at year-end; total liabilities were $6.6 million. The filing reports no credit facility or committed capital source. It does not provide a debt balance as a separate metric.
- Gross margin and operating margin are not meaningful for a company with no product-sales revenue.
- Management said year-end cash was expected to fund projected operating needs for at least 12 months from the filing date, while also stating that additional financing will be needed to advance development and fund operations over the foreseeable future.
Material changes and development progress
- R&D expense rose $17.6 million year over year, mainly due to clinical development and manufacturing costs as tegoprubart programs advanced. G&A increased $3.1 million; 2020 included $2.3 million of restructuring expense and $4.8 million of warrant inducement expense, neither recorded in 2021.
- The Phase 2a ALS trial enrolled 54 participants across four cohorts; enrollment was completed in December 2021. The filing provides no trial efficacy results.
- Regulatory clearances or approvals were obtained to pursue kidney-transplant trials in Canada and the UK, an islet-transplant Phase 2a trial in Canada and the US, and an IgAN Phase 2a study in Australia and New Zealand. The planned IgAN study was to include up to 42 participants.
- Cash declined $29.4 million during 2021. No shares were sold under the company’s $75 million equity-distribution program during the year.
Outlook, risks, and unusual items
- The company expects continuing operating losses and rising development expenses; it may need to raise capital through equity, debt, collaborations, or licensing. Additional financing may be unavailable or dilutive.
- Key risks include early-stage clinical uncertainty and safety, trial enrollment or execution delays, regulatory approval, reliance on third-party manufacturers and CROs, competition, intellectual-property protection, and COVID-19-related disruption. Management reported COVID-19-related study delays and execution inefficiencies, but said impacts had not been material to date.
- At year-end, 108,070 Series X1 preferred shares remained outstanding and 1,145,631 warrants were exercisable for common stock; additional preferred-stock warrants were also outstanding. These securities may contribute to dilution. A January 2022 exchange increased Series X1 preferred shares outstanding and reduced common shares outstanding.
- The filing reports no material legal proceeding requiring accrual. A legacy securities lawsuit was dismissed; the appeal was later dismissed after the insurer made an immaterial settlement payment.
- The financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2021; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Subsequent clinical updates, especially ALS trial data and the initiation, enrollment, and milestones of transplant and IgAN studies.
- Cash use and runway against the company’s stated 12-month funding estimate, including updated financing needs and any use of the $75 million equity facility.
- Potential dilution from preferred stock, warrants, equity awards, and future capital raises.
- Manufacturing capacity, trial timing, and any COVID-19 or other operational disruptions.
- Patent and license status, including remaining milestone obligations and any material change in regulatory or competitive conditions.